Physician profile
Anthony J Ross
NPI 1538237250
$6,395.06
in general payments reported to CMS, 2019-2025
32 companies · $87.40 in 2025
The $87.40 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $751 · 2021: $1,352 · 2022: $947 · 2023: $1,167 · 2024: $518 · 2025: $87.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $699.11 | 2019-2024 | Korlym |
| Amgen INC. | $638.51 | 2019-2023 | Otezla |
| Lilly USA, LLC | $610.90 | 2019-2024 | Mounjaro, Lyumjev, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.73 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $428.00 | 2021-2023 | |
| Pfizer INC. | $382.71 | 2019-2021 | |
| Novo Nordisk INC | $351.24 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $294.56 | 2019-2023 | Farxiga |
| Abbvie INC. | $287.48 | 2021-2023 | Qulipta, Ubrelvy |
| Esperion Therapeutics, INC. | $277.78 | 2020-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $255.00 | 2019-2024 | |
| Astellas Pharma US INC | $242.28 | 2019-2023 | Veozah |
| Mannkind Corporation | $186.86 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.67 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $147.49 | 2023-2024 | Inpefa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $142.17 | 2024-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $130.20 | 2019-2022 | |
| Allergan, INC. | $99.46 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $57.58 | 2019 | |
| Aimmune Therapeutics, INC. | $53.52 | 2024 | |
| Phathom Pharmaceuticals, INC. | $52.11 | 2024 | Voquezna |
| Biogen, INC. | $51.98 | 2021 | |
| Xeris Pharmaceuticals, INC. | $43.91 | 2021 | |
| Arbor Pharmaceuticals, INC. | $40.92 | 2019-2021 | |
| Dexcom, INC. | $36.06 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $35.89 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $34.44 | 2019-2023 | Seglentis, Livalo |
| Eisai INC. | $21.43 | 2021 | |
| Medtronic, INC. | $16.58 | 2024 | Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $16.53 | 2023 | Quviviq |
| Bioventus LLC | $15.55 | 2019 | |
| Forte Bio-Pharma LLC | $14.41 | 2023 | Prolate, Nalocet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.